FRANÇAIS :
Les nouveaux produits du tabac sont le thème de ce rapport de l'OMS qui examine toute une série de problèmes, depuis les dégâts provoqués par les ingrédients toxiques et l'exposition à la nicotine jusqu'au fait que, en l'absence presque totale de réglementation, de nouveaux produits de la nicotine et du tabac font l'objet d'un marketing agressif auprès des utilisateurs potentiels, dont des enfants et des adolescents.
Le groupe de travail de l'OMS sur la réglementation des produits du tabac entend donner des informations scientifiques sur ces produits aux décideurs politiques, et exhorte ces derniers à combler le vide de la réglementation concernant les nouveaux produits de la nicotine et du tabac. Il s'agit notamment des inhalateurs électroniques de nicotine (ENDS), des inhalateurs électroniques ne contenant pas de nicotine (ENNDS) et des produits du tabac chauffés.
Le tabac tue plus de 8 millions de personnes par an ; plus de 7 millions de ces décès sont imputables au tabagisme direct et environ 1,3 million à l'exposition de non-fumeurs à la fumée. Le tabac finit aussi par tuer jusqu'à la moitié des personnes qui en consomment et reste donc une urgence sanitaire mondiale. [Extrait du communiqué de presse]

ENGLISH:
This report of the WHO Study Group on Tobacco Product Regulation provides the Director-General with scientifically sound, evidence-based recommendations for Member States about tobacco product regulation. The outcomes and recommendations address a number of issues concerning novel and emerging nicotine and tobacco products, such as electronic nicotine delivery systems (ENDS), electronic non-nicotine delivery systems (ENNDS) and heated tobacco products (HTPs) and improves understanding of Member States on these products.
The study group reviewed nine background papers and two horizon scanning papers, specially commissioned for its tenth meeting, which addressed the following topics:
- Toxicants in HTPs, exposure, health effects and claims of reduced risk (section 2);
- The attractiveness and addictive potential of HTPs: effects on perception and use and associated effects (section 3);
- Variations among HTPs, considerations and implications (section 4);
- Use of HTPs: product switching and dual or poly product use (section 5);
- Regulations on HTPs, ENDS and ENNDS, with country approaches, barriers to regulation and regulatory considerations (section 6);
- Estimation of exposure to nicotine from use of ENDS and from conventional cigarettes (section 7);
- Exploration of methods for quantifying individual risks associated with ENDS, ENNDS and HTPs: impact on population health and implications for regulation (section 8).
- Flavours in novel and emerging nicotine and tobacco products (section 9);
- Global marketing and promotion of novel and emerging nicotine and tobacco products and their impacts (section 10);
- Forms of nicotine in tobacco plants, chemical modifications and implications for ENDS products (section 11); and
- EVALI: E-cigarette or vaping product use-associated lung injury (section 12).
The Study Group's recommendations seek to promote international coordination of regulatory efforts, the adoption of best practices in product regulation and strengthen product regulation capacity-building across all WHO regions. This report is a ready resource to Member States, based on sound science and support the implementation of the WHO Framework Convention on Tobacco Control (WHO FCTC) by its States Parties.
The report, which is a WHO global public health good will complement the global efforts to strengthen the implementation of WHO FCTC (target 3a of the Sustainable Development Goals), thereby helping reduce tobacco use and improve overall public health at country, regional and global level.
Each chapter of the report has been summarized for regulators to support policy action at country level based on the evidence-based recommendations of the report. These summaries, which are derivative products of the TRS, will be published shortly.